Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis Brigida Anna MaioranoUgo De Giorgithe MeetURO group Systematic Review Open access 22 November 2023 Pages: 1 - 11
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors Serafina MartellaMarco Maria AielloMichele Porcu Review Article 08 December 2023 Pages: 13 - 28
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma Silvia CameraMargherita RiminiAndrea Casadei-Gardini Original Research Article 22 January 2024 Pages: 29 - 39
Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea Yeokyeong ShinBo Hyun MoonChanghoon Yoo Original Research Article 18 December 2023 Pages: 41 - 49
Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08) Hung-Ming WangPei-Jen LouMeng-Che Hsieh Original Research Article Open access 29 January 2024 Pages: 51 - 58
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer Yu SunakawaYasutoshi KubokiTakayuki Yoshino Original Research Article Open access 09 January 2024 Pages: 59 - 69
A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis Ming-Yu LienTzer-Zen HwangMeng-Che Hsieh Original Research Article 02 December 2023 Pages: 71 - 79
Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China Qichen DaiKexin FengYipeng Wang Original Research Article 24 January 2024 Pages: 81 - 93
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8+ Lymphocyte Repopulation in Hepatocellular Carcinoma Eloïne BestionMadani RachidPhilippe Halfon Original Research Article 22 December 2023 Pages: 95 - 106
Pemigatinib: A Review in Advanced Cholangiocarcinoma James E. Frampton Adis Drug Evaluation 11 January 2024 Pages: 107 - 114
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma Nicole L. FranceHannah A. Blair Adis Drug Evaluation Open access 18 January 2024 Pages: 115 - 123
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast Xiuning LeEric NadlerJohn Victor Heymach Correction Open access 09 December 2023 Pages: 125 - 125
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis Brigida Anna MaioranoUgo De Giorgithe MeetURO group Correction Open access 09 December 2023 Pages: 127 - 127
Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer Simon FungYahiya Y. Syed Correction Open access 29 November 2023 Pages: 129 - 129
